Production of eCD4-IG protein

eCD4-IG 蛋白的生产

• 批准号: 10020277
• 负责人: THOMAS VANCOTT
• 金额: $ 19.89万
• 依托单位: ADVANCED BIOSCIENCE LABORATORIES, INC.
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-18 至 2022-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10020277
• 关键词: Contracts; Development; Documentation; HIV-1; Investigational Drugs; Investigator-Initiated Research; National Institute of Allergy and Infectious Disease; Phase; Preclinical Testing; Production; Proteins; flexibility; inhibitor/antagonist; preclinical development; research clinical testing; research study

This contract will provide NIAID with a broad and flexible range of nontraditional, proactive and developmentally-oriented capabilities to provide preclinical development for promising products for when such products emerge from investigator-initiated research studies. These capabilities will allow NIAID to more rapidly and efficiently close development and production gaps. Activities will include but not limited to small-scale production, preclinical testing and documentation leading to Investigational New Drug (IND) submission for Phase I, II, and III clinical testing.

该合同将为 NIAID 提供广泛且灵活的非传统、主动和以开发为导向的能力，以便在研究者发起的研究中出现此类产品时，为有前途的产品提供临床前开发。这些能力将使 NIAID 能够更快速、更有效地缩小开发和生产差距。活动将包括但不限于小规模生产、临床前测试和文件记录，从而提交研究性新药 (IND) 以进行 I、II 和 III 期临床测试。